[lwp_divi_breadcrumbs font_icon=”5||divi||400″ use_custom_home_link=”off” link_color=”#000000″ separator_color=”#000000″ current_text_color=”#FFFFFF” admin_label=”Breadcrumbs” module_class=”insight-breadcrumbs” _builder_version=”4.27.0″ _module_preset=”default” global_colors_info=”{}”][/lwp_divi_breadcrumbs]

Market Insights

Bringing you the trading news around the world.

Chart of the Day: This Drug Developer Rallied and Now It’s Pulled Back

[showmodule id=”58959″]

United Therapeutics spent more than a year consolidating around its 2015 highs. Now the biotech may be attempting a breakout.

Notice the surge to new all-time highs late last month. The rally followed news that the Food & Drug Administration approved its Tyvaso DPI hypertension drug for two applications. (There were worries of a narrower approval.)

UTHR paused for about three weeks and pulled back toward $215. That level is …

For more, please click here to view the related idea and chart analysis on TradingView.

United Therapeutics (UTHR), daily chart with selected patterns and indicators, courtesy of TradingView.

About the author

David Russell is VP of Market Intelligence at TradeStation Group. Drawing on two decades of experience as a financial journalist and analyst, his background includes equities, emerging markets, fixed-income and derivatives. He previously worked at Bloomberg News, CNBC and E*TRADE Financial. Russell systematically reviews countless global financial headlines and indicators in search of broad tradable trends that present opportunities repeatedly over time. Customers can expect him to keep them apprised of sector leadership, relative strength and the big stories – especially those overlooked by other commentators. He’s also a big fan of generating leverage with options to limit capital at risk.